Biopharmaceutical company
Appears in 1 story
Developer of XS411
Nine patients with advanced Parkinson's each received one injection of XS411 into the putamen, the brain region that degenerates in the disease. Six months later, average OFF-state motor scores improved by more than 30 points on the MDS-UPDRS Part III scale, and patients gained over five hours of good ON time per day. The results, presented October 18 at the International Congress of Parkinson's Disease and Movement Disorders, came with zero dose-limiting toxicities, serious adverse events, or graft-induced dyskinesia.
Updated 2 hours ago
No stories match your search
Try a different keyword
How would you like to describe your experience with the app today?
